MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Journal article

BACKGROUND: Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those in the general population. Previous evidence about the effects of lowering cholesterol in people with diabetes has been limited, and most diabetic patients do not currently receive cholesterol-lowering therapy despite their increased risk. METHODS: 5963 UK adults (aged 40-80 years) known to have diabetes, ...

Expand abstract

Authors: Collins, R; Armitage, J; Parish, S; Sleigh, P; Peto, R

• Publication status: Published
• Journal: Lancet
• Volume: 361
• Issue: 9374
• Pages: 2005-2016
• Publication date: 2003-06-01
• DOI: 10.1016/s0140-6736(03)13636-7
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Heart Protection Study Collaborative Group; Humans; Diabetes Complications; Creatine Kinase; Cardiovascular Diseases; Middle Aged; Creatinine; Adult; Prospective Studies; Alanine Transaminase; Risk Factors; Patient Compliance; Lipids; Placebos; Diabetes Mellitus; Aged, 80 and over; Simvastatin; Myocardial Revascularization; Anticholesteremic Agents; Treatment Outcome; Female; Male; Aged